74 filings
8-K
FSTX
F-star Therapeutics Inc
9 Mar 23
Completion of Acquisition or Disposition of Assets
8:27am
8-K
FSTX
F-star Therapeutics Inc
7 Mar 23
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
9:08am
8-K
FSTX
F-star Therapeutics Inc
6 Mar 23
Entry into a Material Definitive Agreement
9:31am
8-K
FSTX
F-star Therapeutics Inc
23 Feb 23
Entry into a Material Definitive Agreement
8:45am
8-K
FSTX
F-star Therapeutics Inc
9 Feb 23
Entry into a Material Definitive Agreement
9:01am
8-K
k1q614fq
1 Feb 23
Entry into a Material Definitive Agreement
8:44am
8-K
n3jk erfxri
30 Dec 22
Entry into a Material Definitive Agreement
8:37am
8-K
yilrook
29 Dec 22
Other Events
9:02am
8-K
4pv65kitmok bikwjdby
21 Dec 22
Entry into a Material Definitive Agreement
6:08am
8-K
4g94p923 todz2fs
19 Dec 22
Entry into a Material Definitive Agreement
11:57am
8-K
jol8yxg zrcwmbw
21 Nov 22
Entry into a Material Definitive Agreement
6:36am
8-K
sbo8bs3q1k04mn7jm
1 Nov 22
Other Events
8:58am
8-K
jze 42cfjgks5
11 Aug 22
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
9:20am
8-K
l1bumdqegwhujpm
23 Jun 22
Invox Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
9:25am
8-K
01g p32x9jbru4
16 Jun 22
Submission of Matters to a Vote of Security Holders
5:18pm
8-K
jlu2zj hkt
10 May 22
F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:22am
8-K
w1j2hb2og696k
14 Mar 22
F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update
8:09am
8-K
d2vkgo3pjg11zx9zi
6 Jan 22
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
8:16am
8-K
2dal95
12 Nov 21
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
8:34am
8-K
jv7b6 y8ret418942
10 Nov 21
F-star Therapeutics Reports Third Quarter 2021 Financial Results
8:30am